The phrase "aggressive dose" is correct and usable in written English.
It can be used in medical or pharmaceutical contexts to describe a higher-than-normal dosage of a medication intended to achieve a rapid or strong effect.
Example: "The doctor prescribed an aggressive dose of the medication to quickly manage the patient's symptoms."
Alternatives: "high dose" or "intensive dosage".
Of note, Pickhardt et al. [27] have shown that MBIR has significant potential when aggressive dose reduction strategies are utilised.
The small sample size and diversity of examinations included in this study did not allow firm conclusions to be drawn in respect to lesion detectability or diagnostic confidence in aggressive dose reduction protocols.
Monitoring of trough serum vancomycin concentrations is recommended for patients receiving aggressive dose targeting, for patients with unstable renal function, and for patients receiving concurrent treatment with nephrotoxic agents.
The authors raise the possibility that more aggressive dose reduction could also be employed on the basis of adipose tissue volumes that could be derived from previous CT scans or from single-slice analysis in those without previous CTs.
Thus, with both prospective and retrospective gating, the data should be acquired during systole (usually 20 50 % phase of the cardiac cycle) with no radiation during the rest of the cycle in prospective ECG triggering and very aggressive dose modulation with retrospective gating, allowing substantial dose savings.
Lepirudin is extensively metabolized and excreted through the kidneys, and aggressive dose reductions are required for therapeutic dosing in patients with renal impairment.
Anyone who does not advocate yet more aggressive doses of neo-liberalism – more privatisation, more cuts to the taxes of the wealthy, more attacks on workers' rights – is liable to come under suspicion, too.
He thinks that by giving "aggressive" doses of OSI's drug, and by testing it both as a single agent and with chemotherapy, he and his colleagues stand a very good chance of getting Tarceva approved.
In the latter study, patients received treatment with a "dose-dense" chemotherapy regimen; if confirmed, the combined data may outline a therapeutic indication for aggressive dose-dense therapy based on tumor TP53/CHEK2 status.
There is limited pharmacokinetic data published on the oral formulation of belinostat, but in study among 15 patients with malignant diseases aggressive dose-escalation resulted in peak plasma levels above 1000nM.
Response rates were dose-dependent, with more aggressive doses yielding greater predicted response.
